GlucoVIP - Diabetes Treatment by Glucobay® With a Special Therapeutic View to Chosen Patient Groups

Bayer

Status: Completed

Conditions: Diabetes Mellitus

Treatments: Drug: Acarbose (Glucobay, BAYG5421)

Study type: Observational

Funder types: Industry

Identifiers

NCT00909051

14284

GB0701 (Other Identifier)

Details and patient eligibility

About

Evaluation of safety and effectiveness of Glucobay® under daily-life treatment conditions in a large sample of patients.

Enrollment: 15,729 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with untreated or pretreated diabetes mellitus or patients for which acarbose is indicated and without acarbose treatment within the last three months before study inclusion. The decision for treatment type and duration is taken by the investigator and is made before inclusion into the study.

Exclusion criteria

• Exclusion criteria must be read in conjunction with the local product information.

Trial design

15,729 participants in 1 patient group

Group 1

Treatment:

Drug: Acarbose (Glucobay, BAYG5421)